FDA Approval Expands Options for ESR1-Mutated Advanced Breast Cancer Patients
The U.S. Food and Drug Administration’s recent decision marks a pivotal moment for advanced breast cancer care. Guardant Health’s Guardant360 CDx test now holds approval as a companion diagnostic for Eli Lilly’s Inluriyo (imlunestrant), directly targeting the significant cohort of patients with ESR1 mutations—estimated to represent 40% of all hormone receptor-positive (HR+), HER2-negative advanced breast cancer cases.
This Is Guardant360 CDx’s Second Breast Cancer Indication
This approval marks the sixth companion diagnostic claim for Guardant360 CDx overall and its second within breast cancer. Guardant360 CDx previously received approval for use with ORSERDU™ (elacestrant) in 2023. The blood-based test has now become the only FDA-approved companion diagnostic for identifying targeted therapy candidates among advanced breast cancer patients with ESR1 mutations. With over 300 million Americans covered by Medicare or commercial insurance for the test, access is already widespread.
| FDA-Approved Indication | Year of Approval | Eligible Patients | Related Therapy |
|---|---|---|---|
| Breast Cancer – ESR1 mutation | 2023 | ER+, HER2-, ESR1-mutated advanced breast cancer (following prior ET) | ORSERDU (elacestrant) |
| Breast Cancer – ESR1 mutation | 2024 | ER+, HER2-, ESR1-mutated advanced breast cancer (following prior ET) | Inluriyo (imlunestrant) |
Clinical Impact: Improved Targeted Treatment for a Significant Patient Segment
In the EMBER-3 Phase 3 clinical trial, Guardant360 CDx was used to identify eligible patients whose disease had progressed after at least one line of endocrine therapy. Results showed that Inluriyo reduced the risk of progression or death by 38% versus continued endocrine therapy—a meaningful benefit for a patient group that previously had limited precision treatment options.
The newly expanded label enables oncologists to offer more tailored therapies with the backing of robust, blood-based genomic profiling. Guardant360 CDx can detect key ESR1 mutations such as E380, V422del, S463, L469, L536, Y537, and D538, helping doctors and patients decide on the most effective next step.
Broader Implications: Liquid Biopsy and Genomic Profiling Take Center Stage
This approval underscores the increasing importance of liquid biopsies and precision diagnostics in oncology. Unlike traditional tissue biopsies, Guardant360 CDx requires only a simple blood draw, allowing more patients to access comprehensive genomic insights rapidly and with minimal discomfort. The test is already FDA-approved for companion diagnostics in several therapies for non-small cell lung cancer, demonstrating a broader utility across cancer types.
“This FDA approval provides another treatment for breast cancer patients with ESR1 mutations for their specific type of cancer along with expanded access to comprehensive genomic profiling with a simple blood draw,” noted Guardant Health’s chairman and co-CEO, Helmy Eltoukhy, highlighting the continued evolution of cancer treatment toward greater personalization.
Takeaway: Patients and Providers Gain More Precision and Options
The addition of Inluriyo to the arsenal of targeted therapies, paired with the widespread availability of Guardant360 CDx, promises tangible improvements in patient outcomes. With ESR1 mutations prevalent in a significant fraction of advanced breast cancers, and the technology now covered by major insurers, more patients could soon benefit from personalized, effective treatment strategies.
While long-term outcomes and future approvals will further define the landscape, this approval is an important stride in precision oncology—one that both patients and providers should keep on their radar.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI